Abstract
Radiation nephropathy and other normal tissue radiation injuries can be successfully mitigated, and also treated, by antagonists of the renin-angiotensin system (RAS). This implies a mechanistic role for that system in radiation nephropathy, yet no evidence exists to date of activation of the RAS by irradiation. RAS antagonists, including angiotensin converting enzyme inhibitors and angiotensin receptor blockers, are the standard of care in the treatment of subjects with other chronic progressive kidney diseases, in which they exert benefit by reducing both glomerular and tubulo-interstitial injury. These drugs are likely to act in a similar way to mitigate radiation nephropathy.
Keywords: Radiation injuries, radiation nephropathy, renin-angiotensin system, angiotensins, captopril, mesangiolysis, Radiation, nephropathy, angiotensin, (TBI), (BMT), Mitigation, (ACE), (BUN), (DMFs), losartan, (HSCT), RAS, (NO), (AcSDKP), bradykinin, (AVE0991), DNA, NADPH oxidase, glomerular
Current Drug Targets
Title: Mitigation of Radiation Injuries via Suppression of the Renin-Angiotensin System: Emphasis on Radiation Nephropathy
Volume: 11 Issue: 11
Author(s): E. P. Cohen, B. L. Fish and J. E. Moulder
Affiliation:
Keywords: Radiation injuries, radiation nephropathy, renin-angiotensin system, angiotensins, captopril, mesangiolysis, Radiation, nephropathy, angiotensin, (TBI), (BMT), Mitigation, (ACE), (BUN), (DMFs), losartan, (HSCT), RAS, (NO), (AcSDKP), bradykinin, (AVE0991), DNA, NADPH oxidase, glomerular
Abstract: Radiation nephropathy and other normal tissue radiation injuries can be successfully mitigated, and also treated, by antagonists of the renin-angiotensin system (RAS). This implies a mechanistic role for that system in radiation nephropathy, yet no evidence exists to date of activation of the RAS by irradiation. RAS antagonists, including angiotensin converting enzyme inhibitors and angiotensin receptor blockers, are the standard of care in the treatment of subjects with other chronic progressive kidney diseases, in which they exert benefit by reducing both glomerular and tubulo-interstitial injury. These drugs are likely to act in a similar way to mitigate radiation nephropathy.
Export Options
About this article
Cite this article as:
P. Cohen E., L. Fish B. and E. Moulder J., Mitigation of Radiation Injuries via Suppression of the Renin-Angiotensin System: Emphasis on Radiation Nephropathy, Current Drug Targets 2010; 11 (11) . https://dx.doi.org/10.2174/1389450111009011423
DOI https://dx.doi.org/10.2174/1389450111009011423 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Relationship between Age-Related Kidney Dysfunction and Framingham Risk Score in Healthy People in China
Current Aging Science Detecting the Association Between Residual Thrombus and Post-thrombotic Classification of Chronic Venous Disease with Range Regression
Reviews on Recent Clinical Trials Targeting the Liver in the Metabolic Syndrome: Evidence from Animal Models
Current Pharmaceutical Design A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin
Current Pharmaceutical Design A Role for Endothelin-1 in Peripheral Vascular Disease
Current Vascular Pharmacology Olive Oil and Haemostasis: Platelet Function, Thrombogenesis and Fibrinolysis
Current Pharmaceutical Design The Protective Effect of DL0805 Derivatives on Pulmonary Artery Cells and the Underlying Mechanisms Study
Current Vascular Pharmacology The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
Current Topics in Medicinal Chemistry Heat Shock Proteins Protect Against Ischemia and Inflammation Through Multiple Mechanisms
Inflammation & Allergy - Drug Targets (Discontinued) Pharmacological Modulations of the Renin-Angiotensin-Aldosterone System in Human Congestive Heart Failure: Effects on Peripheral Vascular Endothelial Function
Current Vascular Pharmacology High-Throughput Functional Genomic Methods to Analyze the Effects of Dietary Lipids
Current Pharmaceutical Biotechnology Ideational Fluency in Patients with Rheumatoid Arthritis
Current Rheumatology Reviews The Relationships between the Transforming Growth Factor-β 1, Age and the Ultrasound Parameters of Arterial Wall
Vascular Disease Prevention (Discontinued) Functional, Genetic and Biochemical Biomarkers of Peripheral Arterial Disease
Current Medicinal Chemistry The Promise of Plant-Derived Substances as Inhibitors of Arginase
Mini-Reviews in Medicinal Chemistry The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target
Current Drug Targets Lipid Lowering Agents and the Endothelium: An Update after 4 Years
Current Vascular Pharmacology Modelling Chemotherapy-induced Cardiotoxicity by Human Pluripotent Stem Cells
Current Drug Targets ACE2 as a Key Target for Treatment of COVID-19 Related Cardiovascular Diseases: Current Progress and Prospect
Current Drug Targets Oxidative Stress and Post-Stroke Depression: Possible Therapeutic Role of Polyphenols?
Current Medicinal Chemistry